Eight Weeks of Ledipasvir/Sofosbuvir in Kidney Transplant Recipients With Hepatitis C Genotype 1 Infection

Short treatment duration of ledipasvir/sofosbuvir (LDV/SOF) has been successfully used to treat hepatitis C virus (HCV) genotype 1 infection in treatment-naive noncirrhotic patients with viral loads (VLs) under 6 million IU/mL. However, this short duration has not been studied in renal transplant re...

Descripción completa

Detalles Bibliográficos
Autores principales: Husson, Jennifer S., Ravichandran, Bharath, Jonchhe, Srijana, Kottilil, Shyamasundaran, Wilson, Eleanor
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2017
Materias:
Infectious Disease
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5828686/
https://www.ncbi.nlm.nih.gov/pubmed/29536030
http://dx.doi.org/10.1097/TXD.0000000000000744
_version_ 1783302682286489600
author Husson, Jennifer S.
Ravichandran, Bharath
Jonchhe, Srijana
Kottilil, Shyamasundaran
Wilson, Eleanor
author_facet Husson, Jennifer S.
Ravichandran, Bharath
Jonchhe, Srijana
Kottilil, Shyamasundaran
Wilson, Eleanor
author_sort Husson, Jennifer S.
collection PubMed
description Short treatment duration of ledipasvir/sofosbuvir (LDV/SOF) has been successfully used to treat hepatitis C virus (HCV) genotype 1 infection in treatment-naive noncirrhotic patients with viral loads (VLs) under 6 million IU/mL. However, this short duration has not been studied in renal transplant recipients (RTRs), a patient population on lifelong immunosuppression. Here, we describe 3 RTRs who received 8 weeks of LDV/SOF, meeting the standard criteria for shortened treatment duration. All 3 patients tolerated treatment well and achieved sustained virologic response at 12 weeks (SVR 12).
format Online
Article
Text
id pubmed-5828686
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-58286862018-03-13 Eight Weeks of Ledipasvir/Sofosbuvir in Kidney Transplant Recipients With Hepatitis C Genotype 1 Infection Husson, Jennifer S. Ravichandran, Bharath Jonchhe, Srijana Kottilil, Shyamasundaran Wilson, Eleanor Transplant Direct Infectious Disease Short treatment duration of ledipasvir/sofosbuvir (LDV/SOF) has been successfully used to treat hepatitis C virus (HCV) genotype 1 infection in treatment-naive noncirrhotic patients with viral loads (VLs) under 6 million IU/mL. However, this short duration has not been studied in renal transplant recipients (RTRs), a patient population on lifelong immunosuppression. Here, we describe 3 RTRs who received 8 weeks of LDV/SOF, meeting the standard criteria for shortened treatment duration. All 3 patients tolerated treatment well and achieved sustained virologic response at 12 weeks (SVR 12). Lippincott Williams & Wilkins 2017-11-03 /pmc/articles/PMC5828686/ /pubmed/29536030 http://dx.doi.org/10.1097/TXD.0000000000000744 Text en Copyright © 2017 The Author(s). Transplantation Direct. Published by Wolters Kluwer Health, Inc. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (http://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
spellingShingle Infectious Disease
Husson, Jennifer S.
Ravichandran, Bharath
Jonchhe, Srijana
Kottilil, Shyamasundaran
Wilson, Eleanor
Eight Weeks of Ledipasvir/Sofosbuvir in Kidney Transplant Recipients With Hepatitis C Genotype 1 Infection
title Eight Weeks of Ledipasvir/Sofosbuvir in Kidney Transplant Recipients With Hepatitis C Genotype 1 Infection
title_full Eight Weeks of Ledipasvir/Sofosbuvir in Kidney Transplant Recipients With Hepatitis C Genotype 1 Infection
title_fullStr Eight Weeks of Ledipasvir/Sofosbuvir in Kidney Transplant Recipients With Hepatitis C Genotype 1 Infection
title_full_unstemmed Eight Weeks of Ledipasvir/Sofosbuvir in Kidney Transplant Recipients With Hepatitis C Genotype 1 Infection
title_short Eight Weeks of Ledipasvir/Sofosbuvir in Kidney Transplant Recipients With Hepatitis C Genotype 1 Infection
title_sort eight weeks of ledipasvir/sofosbuvir in kidney transplant recipients with hepatitis c genotype 1 infection
topic Infectious Disease
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5828686/
https://www.ncbi.nlm.nih.gov/pubmed/29536030
http://dx.doi.org/10.1097/TXD.0000000000000744
work_keys_str_mv AT hussonjennifers eightweeksofledipasvirsofosbuvirinkidneytransplantrecipientswithhepatitiscgenotype1infection
AT ravichandranbharath eightweeksofledipasvirsofosbuvirinkidneytransplantrecipientswithhepatitiscgenotype1infection
AT jonchhesrijana eightweeksofledipasvirsofosbuvirinkidneytransplantrecipientswithhepatitiscgenotype1infection
AT kottililshyamasundaran eightweeksofledipasvirsofosbuvirinkidneytransplantrecipientswithhepatitiscgenotype1infection
AT wilsoneleanor eightweeksofledipasvirsofosbuvirinkidneytransplantrecipientswithhepatitiscgenotype1infection

Ejemplares similares